The European Commission dashed hopes on Thursday of leniency for mergers within the telecommunications industry as Cecilio Madero, deputy director-general for antitrust at the regulator, offered a frank remark regarding the subject at a conference. The official stated that even if telecoms were to request leniency for proposed deals, there is not enough evidence the support may of their claims that operators’ investments would rise in response to growth from merger deals. According to reports, the request for merger leniency is likely a response to increased pressure on the companies who are struggling to keep up their infrastructure and meet demands of a society dependent on smartphones and tablets that use more data. Teleco companies across Europe have been struggling with four straight years of revenue declines, say reports, and are now looking to break the trend with big-deal mergers. Vodafone, Orange and KPN have all expressed the need to become part of acquisitions in their efforts to finance network and infrastructure investments, but the Commission, as reiterated by Madero, is not convinced that mergers will allow companies to increase their investments.
Full Content: Yahoo News
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas